LGC’s board and executive management teams have an extensive understanding of the scientific marketplaces we serve. They are committed to supporting and creating opportunities for our employees worldwide, delivering high quality performance and services for our customers.
David P. King is a respected senior healthcare executive who operates with a strong emphasis on deeply understanding the healthcare industry, strategic planning, and staying ahead of rapidly evolving industry trends and challenges. He uses the insights gained in his 20+ year healthcare career in providing strategic and operational advice to a number of industry stakeholders.
David served for over 13 years as executive chair and CEO of Laboratory Corporation of America Holdings (Labcorp). Under his leadership, Labcorp transformed from a pure-play U.S. testing laboratory into a leading global life sciences company — tripling in size through a combination of organic growth and strategic acquisitions, entering the Fortune 500, and being named to Fortune’s List of World’s Most Admired Companies.
In 2019, Forbes named David to its list of America’s Most Innovative Leaders. David’s board service includes non-executive chair of Privia Health (NASDAQ:PRVA) and non- executive chair of ZimVie (NASDAQ:ZIMV). He also serves on a number of private boards.
David’s community service includes board member of Novant Health, a super-regional integrated health system, and advisory board and executive committee member of Duke University’s Robert J. Margolis, MD, Center for Health Policy. David previously served on the board of Cardinal Health (NYSE: CAH), a Fortune 20 healthcare company, and the American Clinical Laboratory Association, where he served as board chair from 2010 to 2014.
David holds a bachelor’s degree, cum laude, from Princeton University and a Juris Doctor, cum laude, from the University of Pennsylvania Law School.
Prior to joining the Group, Tish served as the Execute Vice President of Applied Solutions Strategy, Marketing and Innovation (SMI) for MilliporeSigma, a Merck KGaA Company. Before the acquisition of Sigma-Aldrich by Merck KGaA, Tish was part of Sigma-Aldrich from 2005 – 2015 and served as Vice President of the Diagnostics & Testing team as well as Vice President of the Global Custom Products business focused on oligonucleotides and peptides.
From 1999 to 2005, Tish was with Applied Biosystems serving as Director, R&D Proteomics & Small Molecule Division with a focus on mass spectrometry. Tish has enjoyed a career directing multidisciplinary product development in the life science and pharmaceutical markets and has a successful track record managing in both global multinational environments and small entrepreneurial settings.
Professionally, Tish is the recipient of several scientific achievement awards; she is a published author of both scientific articles and patents. Tish completed her PhD in Organic Chemistry from The Pennsylvania State University, State College, Pennsylvania, USA.
James joined Astorg in 2019 and is a member of the Investment Team. Prior to this, he spent 20 years at ICG where he was Managing Director responsible for investments in the Nordic Region and a member of the Investment Committee.
James started his career at Deloitte where he qualified as a chartered accountant.
Marcus Kaeller was appointed as Chief Financial Officer (CFO) in June 2024.
Marcus was most recently Group CFO and Managing Director of Affidea, the pan-European diagnostic imaging and community-based polyclinic and specialist healthcare services provider - operating 356 centres in 15 European countries. Prior to this, he has held senior financial leadership roles at education multinational Laureate Education, the medical technologies business Stryker, as well as AstraZeneca, having started his career working at Unilever and Accenture.
Marcus has an undergraduate degree in Business Administration and Economics from Edinburgh University, is a Qualified Accountant by the Chartered Institute of Management Accountants in London and has an MBA from London Business School.
François joined Astorg in 2012 and is a member of the Investment team.
He has been involved in a number of transactions including Megadyne, Linxens, IQ-EQ, Flowbird, Audiotonix and Anaqua. Prior to joining Astorg, François was with Intermediate Capital Group Plc from 1997. There, he was appointed Managing Director in 2005, then became progressively more responsible for ICG's investment activities in Mezzanine and Equity worldwide. Previously, he was an Associate Director at the LBO division of Société Générale in London and began his career at the M&A division of HSBC in London.
François graduated from the Institut d'Etudes Politiques de Paris and Université de Paris-Dauphine.
Matthew joined Cinven in 2010 and is a member of its Healthcare sector team. He has been involved in a number of transactions, including Medpace, NPS, Pronet, Sebia, STADA, Labco and Synlab (merged under the Synlab brand), Envirotainer and Ufinet.
Prior to joining Cinven, Matthew worked in the Investment Banking Division of Citigroup in London, advising on M&A and restructuring deals across a range of sectors including consumer, real estate, TMT and healthcare.
Matthew graduated from Imperial College London with a Master’s Degree in Physics.
Euan O’Sullivan - President & CEO, Interim GM, Axolabs
Euan was appointed President and Chief Executive Officer in September 2021.
Having initially joined LGC as a Non-Executive Director, a role he filled from 2007 to 2010, Euan took up an Executive role as Corporate Development Director from July 2010 before being appointed Managing Director of the Standards division in 2012 and building LGC’s wider Quality Assurance business over the following eight years.
Euan has served as an Executive Director on the Board of LGC since 2017 and was appointed President and Chief Operating Officer (COO) in June 2020.
Euan joined LGC from the UK mid-market private equity house LGV Capital, where he was an Investment Director. Prior to that, Euan spent the early part of his career in business strategy consulting and corporate finance. Euan is a graduate of University College, Oxford.
Supraj joined Cinven in 2004 and leads its Healthcare Sector team. He sits on the firm’s Investment and Executive Committees and has worked on a number of transactions, including Ahlsell, Barentz, Bioclinica, CeramTec, JLA, Medpace, National Seating & Mobility, Phadia, Sebia and STADA.
Prior to joining Cinven, Supraj was at The Boston Consulting Group, where he worked on projects in the healthcare and financial services sectors.
Supraj graduated from Cambridge University with undergraduate and postgraduate degrees in Medical Sciences.
Nicolas joined the Board of LGC in April 2016. Prior to joining the Group, Nicolas served as Senior Vice President at Agilent Technologies Inc., as well as President of its Life Sciences Group (2009 to 2013) and Vice President and General Manager of the Life Sciences Division (2006 to 2009).
Prior to joining Agilent Technologies Inc., Nicolas was with Bio-Rad Laboratories, Inc. (2005 to 2006) and served as the Life Science Group’s Group Operations Officer, heading five business divisions spanning life science and food science. His time at Stratagene Corporation (2001 to 2005) saw him serve as Senior Vice President of Marketing, Sales and Business Development for the first two years and then as Chief Operating Officer.
Professionally, Nicolas is currently a Thematic Partner with Summa Equity AB and serves on several public and private BODs. He also serves as an industry consult to PE firms across the Global Life Science and Diagnostics markets.
Euan O’Sullivan - President & CEO, Interim GM, Axolabs
Euan was appointed President and Chief Executive Officer in September 2021.
Having initially joined LGC as a Non-Executive Director, a role he filled from 2007 to 2010, Euan took up an Executive role as Corporate Development Director from July 2010 before being appointed Managing Director of the Standards division in 2012 and building LGC’s wider Quality Assurance business over the following eight years.
Euan has served as an Executive Director on the Board of LGC since 2017 and was appointed President and Chief Operating Officer (COO) in June 2020.
Euan joined LGC from the UK mid-market private equity house LGV Capital, where he was an Investment Director. Prior to that, Euan spent the early part of his career in business strategy consulting and corporate finance. Euan is a graduate of University College, Oxford.
Marcus Kaeller was appointed as Chief Financial Officer (CFO) in June 2024.
Marcus was most recently Group CFO and Managing Director of Affidea, the pan-European diagnostic imaging and community-based polyclinic and specialist healthcare services provider - operating 356 centres in 15 European countries. Prior to this, he has held senior financial leadership roles at education multinational Laureate Education, the medical technologies business Stryker, as well as AstraZeneca, having started his career working at Unilever and Accenture.
Marcus has an undergraduate degree in Business Administration and Economics from Edinburgh University, is a Qualified Accountant by the Chartered Institute of Management Accountants in London and has an MBA from London Business School.
Dr Bharathi Anekella - Executive VP, D&G Innovation Hub
Bharathi joined SeraCare in 2000, which was subsequently acquired by LGC. She was appointed Executive Vice President for LGC’s Diagnostics & Genomics Innovation Hub in April 2024.
Bharathi served as Senior Vice President of Product Development and Technical Operations from 2014 and, in 2021, assumed leadership of LGC Clinical Diagnostics as its Executive Vice President and General Manager.
Prior to joining SeraCare, Bharathi was a lead scientist at DNA Technologies where she developed molecular assays and managed contract manufacturing. She has more than 25 years of experience in technology and product development in infectious diseases, oncology, genetic diseases and recombinant virus.
Bharathi has a PhD in Microbiology from Osmania University, India.
Manjeet joined LGC in April 2021 as Chief Digital and Information Officer and was appointed to Chief Transformation Officer in July 2022.
Following his service with the Royal Air Force, Manjeet has enjoyed an extensive career in pharmaceuticals with GlaxoSmithKline. He has a wealth of experience in leading global technology functions across the entire pharmaceutical and vaccine verticals. In addition to technology leadership, Manjeet has extensive experience of managing enterprise-wide business transformation programmes.
Manjeet holds a Bachelor’s Degree in Engineering and a Diploma in Accounting and Finance.
Julie joined LGC in August 2022 as Chief People Officer.
During her career, Julie has held a variety of HR leadership roles, including leading the HR functions in Horizon Discovery Plc, Getronics and CPA Global. Julie has both private equity and listed company experience.
Julie holds a Bachelor’s Degree in Ancient History and Archaeology and a Master’s in Contemporary Japan.
Lee originally joined LGC in July 2021 as Chief Technology Officer and was appointed Chief Digital and Information Officer in July 2022.
Prior to joining LGC, Lee worked at Walgreens Boots Alliance (WBA) where he led Global IT Services and Programmes across the organisation’s corporate and retail environments, including supporting retailers’ efforts during the COVID-19 pandemic. Before moving to WBA, Lee had an extensive career working in life sciences at GlaxoSmithKline where he had roles covering infrastructure, enterprise platforms and corporate business services.
Lee holds a Bachelor’s Degree in Business and Computing and a Post Graduate Diploma in Strategy and Innovation from Oxford Saïd Business School.
Sanjeev was appointed Executive Vice President and General Manager, Corporate Development, Assure & NLS in May 2024. He joined LGC in 2019, and prior to his current role served as Senior Vice President, Corporate Strategy, Development and Communications.
Prior to joining LGC, Sanjeev gained extensive experience in the life sciences, healthcare and industrials sectors, working for international organisations including Hesira, Danaher, UBS and KPMG.
Sanjeev holds a Bachelor’s Degree in Chemistry from the University of East Anglia and is a qualified Chartered Accountant.
Bruno brings more than 28 years of global experience in the life sciences industry, including the laboratory, pharmaceutical, and diagnostic market segments with senior strategic roles in product management, sales and marketing, R&D, Operations and Process Excellence functions.
Before joining LGC , Bruno held multiple leadership positions at Leica Microsystems (a Danaher company) for 5 years, at Millipore (now part of Merck KGaA) for 22 years and most recently serving as CCO at Olink Proteomics.
Bruno holds a Master’s degree in Organic Chemistry from École Nationale Supérieure de Chimie de Clermont-Ferrand (ENSCCF) and was actively involved -as Chairman and/or members- in various standard organization committees during all his career.
Helen Watson - General Counsel & Company Secretary
With over 25 years of legal experience, Helen has worked in various senior global roles for leading multinational companies including Vodafone and Cable & Wireless, having trained and qualified at Linklaters.
Most recently, she was Legal Director for Vodafone’s Internet of Things (IoT) business, leading on legal/risk matters for their global management team, and was also Legal Director for Vodafone’s Business Strategy and M&A Board. Helen also has extensive Environmental, Social & Governance (ESG) experience from her time as Company Secretary for Vodafone Group’s ESG Committee.
Prior to pursuing a career in law, Helen’s undergraduate degree at Cambridge University was in Natural Sciences (Genetics and Biochemistry).
Ken Yoon - Executive VP & GM, Diagnostics & Genomics
Ken is Executive Vice President (EVP) and General Manager (GM) for Diagnostics & Genomics at LGC. He first joined the company in September 2022 as EVP and GM for LGC’s Standards business unit.
Prior to joining LGC, Ken co-founded Fortis Life Sciences in 2020 where he served as Chief Operating Officer. Before Fortis, he held several senior executive roles at MilliporeSigma over the course of 10 years, most recently as the Vice President and Head of the Lab and Specialty Chemicals Business Unit. Earlier in his career, Ken worked as a management consultant for McKinsey and Company, and as a postdoctoral fellow at the Novartis Institute for Biomedical Research.
Ken graduated with a PhD in Neuroscience from Yale University, and a BS with Honors in Chemistry from Stanford University.
